- The article discusses how the mention of GLP-1 agonists, weight-loss medications, and obesity drugs during earnings calls has been increasing, leading to questions about the potential impact on sales for healthcare and consumer companies. The mention of these drugs and their growing popularity has sparked investor interest, with some companies experiencing stock price declines due to concerns about the impact on their businesses. However, there is still uncertainty around the long-term use, pricing, and insurance coverage of these drugs.
- Amgen (AMGN) stock went down by -0.02% last night, likely due to concerns about the impact of weight-loss medications, such as GLP-1 agonists, on the healthcare and consumer industries. These medications have gained popularity and are being discussed extensively, leading to questions about their potential effect on sales for companies across the globe. The growing interest in weight-loss medications was sparked by Walmart's mention of a slight pullback in food demand from customers taking these treatments. While some companies have expressed concerns, analysts believe that weight-loss medications could become the best-selling drug class in the pharmaceutical industry.
- The article discusses how a drop in corporate dealmaking in 2023 has led to uncertainty and a decrease in mergers and acquisitions (M&A) activity. Factors such as geopolitical conflicts, regulatory hurdles, concerns about an economic slowdown, and hostility from antitrust regulators have all contributed to the decline in M&A. However, there are some positive signs, as companies are using their stocks as currency for acquisitions and are more willing to battle regulators in court. Investment bankers remain hopeful that dealmaking activity will pick up once uncertainty subsides. The article does not mention why Amgen (AMGN) stock specifically went down.
- The article states that the Amgen (AMGN) stock went down by -3.37% last night, but does not provide a specific reason for the decrease in the stock price.
- The article does not mention anything about Amgen (AMGN) stock going down, so it is not clear why it experienced a decrease. The article is instead about a podcast episode featuring former Merck CEO Ken Frazier discussing his career, decisions he made as CEO, and his involvement in social issues.
- Amgen (AMGN) stock went down by -3.37% due to the challenging economic environment, rising cost of capital, and disappointing trial results announced by biotech companies in the portfolio.
- The article discusses various companies that have announced layoffs, including Nextdoor, Pfizer, Panera, Charles Schwab, Condé Nast, Splunk, Amgen, Ford, Stellantis, Nokia, LinkedIn, and many others. Amgen's layoffs are expected to affect 350 employees, primarily in roles where Amgen and Horizon Therapeutics overlapped.
- Amgen Inc's stock went up by 0.79% after releasing new data on its Phase 2 study of dazodalibep for Sjögren's, a chronic autoimmune disorder that affects the glands producing moisture in the body.
- The article discusses two dividend-paying ETFs, the Vanguard Dividend Appreciation ETF and the Schwab U.S. Dividend Equity ETF, that offer stable dividends and solid returns. While the Vanguard ETF focuses on companies with a track record of consistently increasing dividends, the Schwab ETF includes stocks with at least 10 years of dividend payouts. The article does not provide a specific explanation for why Amgen (AMGN) stock went up.
- The article discusses the success and impact of Mark Cuban Cost Plus Drug Co., an online pharmacy that offers medications at significantly discounted prices by cutting out middlemen such as pharmacy benefit managers. The company's transparent pricing and affordability have garnered attention and sparked calls for reform in the pharmaceutical industry. The founder, Dr. Alex Oshmyansky, hopes his business model will encourage others to follow suit and make a change in the industry. The success of Cost Plus Drugs has also affected the stocks of major drugmakers and pharmacy benefit managers, prompting investors and industry analysts to consider the future of companies currently dominating the pharmaceutical supply chain. The article highlights the need for transparency in drug pricing and the financial burden faced by many patients due to the high cost of prescription drugs.
- The article discusses a new study by deCODE genetics, a subsidiary of Amgen, that provides insights into clonal hematopoiesis, a condition where a single lineage of stem cells expands and becomes the source of a significant number of blood cells. The study found that clonal hematopoiesis is common in the elderly and increases the risk of developing hematological neoplasia and other diseases, with smoking being a major contributing factor. Amgen's stock went up by 1.1% last night, but the article does not directly state why the stock went up.
- Coherus BioSciences, Inc. has reported a 27% increase in net revenue for the third quarter, leading to a 1.1% increase in Amgen (AMGN) stock, as the company's Chairman and CEO stated that they expect further revenue growth driven by various products while focusing on returning to profitability.
- Amgen (AMGN) stock went up by 1.1% last night, but the article does not provide specific reasons for the increase.
- Analysts are optimistic about Amgen Inc.'s stock as they anticipate positive news from the company's pipeline of cancer, obesity, and cardiovascular drugs, despite a recent setback with their cancer drug Lumakras.
- Amgen (AMGN) stock saw a 4.55% increase last night after an analyst upgrade, citing the expanding pipeline optionality after the acquisition of Horizon Therapeutics and the potential launch of major pipeline candidates in the late decade as the reasons behind the upgrade.
- The article discusses how Amgen stock experienced a 4.55% increase and reached a 10-month high due to an unexpected upgrade, which was attributed to a positive outlook on the company's future after the Horizon acquisition.
- Amgen (AMGN) stock went up 4.55% as part of a positive trading session for the stock market, with the S&P 500 and Dow Jones Industrial Average also rising; the reason for the increase in Amgen stock is not mentioned in the article.
- Amgen (AMGN) stock went up by 4.55% following an upgrade from Leerink Partners, citing the biotech company's promising pipeline newsflow as the reason for the boost.
- Amgen's stock, AMGN, went up by 4.55% due to positive news about its pipeline of cancer, obesity, and cardiovascular drugs, despite a setback with its cancer drug Lumakras. Analysts believe that the accelerating pipeline newsflow and potential blockbuster candidates will bolster the stock's valuation. However, there is a risk that the FDA could rescind its tentative approval of Lumakras, leading analysts to lower their sales estimates for the drug. Nonetheless, Amgen's broader pipeline potential and acquisition of Horizon Therapeutics are expected to continue boosting earnings expectations.
- The article states that Ligand Pharmaceuticals has announced that its partner Jazz Pharmaceuticals has been granted marketing authorization for Enrylaze in the European Union, expanding the market opportunity for one of Ligand's key products, and this news may have caused Amgen (AMGN) stock to go down by -0.63% last night.
- The Amgen (AMGN) stock went down by -0.63% last night, but the article does not provide a specific reason for the decrease in stock value.
- Amgen Inc. (AMGN) stock went down 0.63% due to a poor trading session in the stock market, with the S&P 500 and Dow Jones Industrial Average also experiencing losses, and it closed $28.97 below its 52-week high achieved on November 8th.
- The article discusses how major drugmakers like Amgen, Bayer, and Novartis are using artificial intelligence (AI) to expedite and streamline the process of clinical trials, potentially saving time and money in drug development. Amgen's use of AI tool ATOMIC, for example, has helped cut the time to enroll patients in trials in half. The stock of Amgen (AMGN) went down last night, but the article does not provide a specific reason for this decline.
- The article discusses Neumora Therapeutics' plans to raise up to $264.8 million in its U.S. initial public offering, which is backed by Amgen and SoftBank. The increase in the Amgen stock could be attributed to the positive news of its investment in Neumora Therapeutics and the potential success of the IPO.
- Amgen (AMGN) stock went up by 0.88% last night, but the article does not provide a specific reason for the increase.
- Amgen (AMGN) stock went up by 0.88% after the company announced its participation in the Bank of America Merrill Lynch Global Healthcare Conference, where the executive vice president and chief financial officer will present, indicating potential positive developments in the company's business.
- Amgen (AMGN) stock went up by 0.88% last night, and the article highlights the strong performance of Nvidia in the stock market driven by the world of artificial intelligence, while also noting that the healthcare sector has been disregarded this year. The article recommends buying top-yielding stocks in the healthcare sector, including AbbVie Inc. (ABBV) and Amgen Inc. (AMGN), with Amgen being seen as a safer way to play the potential growth in biosimilars.
- Neumora Therapeutics, a biopharmaceutical company backed by Amgen, plans to sell shares in an IPO, which is expected to raise $227.5 million, potentially increasing Amgen's stake in the company and boosting its stock.
- The Amgen Inc. (AMGN) stock went up by 1.06% last night, possibly due to the company's solid 7-day performance and its improved bottom line, although the overall market return has been better than the stock's performance in the last five years.
- Amgen (AMGN) stock went up by 1.06% last night, however, the reason for the increase is not mentioned in the article.
- The article discusses how Amgen (AMGN) stock has consistently outperformed the market over the past 15 years, with an average annual return of 9.73%. The increase in the stock's value can be attributed to the company's market capitalization of $140.18 billion and its strong performance in the market.
- The article discusses reasons why Amgen (AMGN) stock could be a good investment for dividend growth investors, including the company's strong second-quarter results, with total revenue growth of 5.9% (7% excluding currency translation effects) and a 7.5% increase in adjusted diluted EPS. The company's impressive product portfolio, including recently launched products and compounds in its clinical development pipeline, is expected to support future growth. Amgen also offers a dividend yield of 3.2%, more than double the S&P 500 index's average yield, and has a low dividend payout ratio, indicating room for future growth. The stock's current valuation, with a forward P/E ratio slightly above the industry average, makes it attractive for dividend growth investors.
- The article discusses TScan Therapeutics, a clinical-stage biopharmaceutical company focused on developing T cell receptor-engineered T cell therapies for cancer treatment, and its financial results for the second quarter of 2023. The article also mentions that Amgen, a collaboration partner, provided $30 million in proceeds to fund the company through 2026. The reason for the increase in Amgen's stock is not mentioned in the article.
- Genelux, a clinical-stage biotech company specializing in immunotherapies for difficult-to-treat cancers, saw its stock rise after announcing management changes, including the addition of two executives from Amgen, as it gets closer to its first launch with its lead therapy, Olvi-Vec, which is in a phase 3 trial and could soon have its biologics license application sent to the FDA.
- Amgen Inc. (AMGN) stock went up by 0.14% last night, and the article discusses the company's debt and its potential impact on its riskiness. The article notes that while Amgen does have a significant amount of debt, it also has a large amount of cash and a strong ability to generate free cash flow, which suggests that it can handle its debt. However, it is still important to monitor the company's debt levels going forward.
- The article discusses Eli Lilly's recent success and its impact on the company's stock, highlighting the potential downside of its high valuation. It also mentions the challenges Lilly faces, such as generic competition and declining demand for COVID-19 solutions. The article concludes with a discussion on the uncertainty surrounding Lilly's outlook and suggests looking for other growth opportunities.
- Cheaper versions of AbbVie's arthritis drug Humira are likely to lead to further scrutiny of pharmacy benefit managers (PBMs), who negotiate drug prices, by lawmakers and the federal government, which could impact the stock price of pharmaceutical company Amgen (AMGN); the stock may have gone down due to concerns about the pricing strategy of PBMs and the potential impact on Amgen's biosimilar drug Amjevita.
- The article discusses two high-yield dividend stocks in the healthcare sector: Amgen (AMGN) and Bristol Myers Squibb (BMY). Amgen's stock went down by -0.05% last night. The reasons for the decrease in Amgen's stock may be due to headwinds such as competition, a thin clinical pipeline, and lack of a potent growth driver. However, Amgen is still considered a strong buy due to its generous dividend program, attractive valuation, and healthy underlying business.
- The article reports that Amgen's stock (AMGN) went down 1.94% in the latest trading session, underperforming the S&P 500, and attributes this decline to potential changes in analyst estimates for the company's earnings.
- The article discusses the recent drop in Amgen Inc. (AMGN) stock by 1.94% and examines the underlying fundamentals of the company to understand why the stock has gone down. One possible reason is that despite a compound earnings per share (EPS) growth of 37% per year over the past five years, the share price gain has only been 3% over the same period, indicating that the broader market has become more cautious towards the stock. Additionally, while Amgen's total shareholder return (TSR) over the last five years was 32%, better than the share price return, the stock has underperformed the market this year, with shareholders down 7.3% compared to a market that is up 12%. However, long-term shareholders have still made a gain of 6% per year over the past five years, suggesting that the recent sell-off may present a buying opportunity.